FENC vs. CGEM, LENZ, AUTL, VECT, TECX, CRGX, HUMA, DNA, TRML, and PROK
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Autolus Therapeutics (AUTL), VectivBio (VECT), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Humacyte (HUMA), Ginkgo Bioworks (DNA), Tourmaline Bio (TRML), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
Fennec Pharmaceuticals (NASDAQ:FENC) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
Fennec Pharmaceuticals currently has a consensus price target of $13.67, suggesting a potential upside of 146.69%. Cullinan Therapeutics has a consensus price target of $31.67, suggesting a potential upside of 208.64%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Fennec Pharmaceuticals.
55.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Cullinan Therapeutics had 2 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 1 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 1.44 beat Cullinan Therapeutics' score of 0.49 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Fennec Pharmaceuticals received 158 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 66.45% of users gave Fennec Pharmaceuticals an outperform vote.
Fennec Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cullinan Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Cullinan Therapeutics' return on equity of -26.54% beat Fennec Pharmaceuticals' return on equity.
Summary
Fennec Pharmaceuticals beats Cullinan Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 1/21/2025 by MarketBeat.com Staff
